NLRP3 and chronic kidney disease: BTK and NLRP3 being expressed in different cells involved in the pathogenesis of kidney injuries (i.e., epithelial cells, macrophages and B-cells), we put forward the hypothesis that ibrutinib may prevent AKI or transition from AKI to CKD by targeting immune and tubular cells.